CHMP Issues Negative Opinion on Translarna™ Following European Commission Request for Review PR Newswire WARREN, N.J., June 28, 2024 - PTC to...
PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PR Newswire WARREN, N.J., June 21, 2024 WARREN, N.J., June 21...
Interim PIVOT-HD Results Demonstrate Evidence of Favorable CNS Biomarker and Clinical Effects at Month 12 in Huntington's Disease Patients PR...
PTC Therapeutics to Participate at Upcoming Investor Conference PR Newswire WARREN, N.J., May 29, 2024 WARREN, N.J., May 29, 2024 /PRNewswire/...
PTC Therapeutics Announces Validation of Sepiapterin European MAA PR Newswire WARREN, N.J., May 28, 2024...
PTC Therapeutics Announces European Commission Returns Translarna™ Opinion to CHMP For Re-evaluation PR Newswire WARREN, N.J., May 20, 2024...
PTC Therapeutics Announces FDA Acceptance and Priority Review of the BLA for Upstaza™ PR Newswire WARREN, N.J., May 14, 2024 - PDUFA target...
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.